ReviewMolecular biology reports2020
The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.
Review in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Differentially expressed microRNAs in human depression: a systematic review of case-control and longitudinal studies.BMC psychiatry · 2025Pooled it
- Association between the BDNF Val66Met polymorphism and major depressive disorder: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Pooled it
- Pooled it
- Association of peripheral manifestation of brain-derived neurotrophic factor with depression: A meta-analysis.Brain and behavior · 2022Pooled it
- A longitudinal PET study on changes in brain norepinephrine transporter availability following duloxetine treatment in major depressive disorder.The international journal of neuropsychopharmacology · 2025Trial
- Trial
- Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study.Translational psychiatry · 2022Trial
- Peripheral S-(PGJBMC psychiatry · 2026Article
- Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations.Clinical pharmacology and therapeutics · 2026Article
- Ecologically-Valid Emotion Signatures Enhance Mood Disorder Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Associations of cardiorespiratory fitness and muscular fitness with plasma levels of endocannabinoids and their analogues in adults with diagnosed depression: SONRIE study.European archives of psychiatry and clinical neuroscience · 2026Article
- Aberrant MicroRNA-124 expression and methylation in the dorsolateral prefrontal cortex of depressed subjects.Journal of psychiatric research · 2026Article
- Altered Plasma Endocannabinoids and Oxylipins in Adolescents with Major Depressive Disorders: A Case-Control Study.Nutrients · 2026Article
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Electroencephalogram Gamma Band Power Correlates with Anhedonia in a Community Sample.Journal of personalized medicine · 2025Article
- The Art of Nanoimmunobiotechnomedicine in Depression Management.Advanced pharmaceutical bulletin · 2025Review
- Oxidative stress and cognitive function in Chinese patients with major depressive disorder: the mediating role of depression severity.BMC psychiatry · 2025Article
- Investigation of depression-like phenotypes and their behavioral correlates in cynomolgus monkeys (Macaca fascicularis).BMC zoology · 2025Article
- Antidepressant-like Properties of a Selenium-Containing Pyridinium Salt Explored through In Vitro, In Vivo, and In Silico Approaches.ACS chemical neuroscience · 2025Article
- Elucidating the Antidepressant-Like Effect of Tannic Acid in Mice: Modulation of Serotonergic System and Pro-Inflammatory Mediators.Molecular neurobiology · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is considered a serious public health issue that adversely impacts an individual's quality of life and contributes significantly to the global burden of disease. The clinical heterogeneity that exists among patients limits the ability of MDD to be accurately diagnosed and currently, a symptom-based approach is utilized in many cases. Due to the complex nature of this disorder, and lack of precise knowledge regarding the pathophysiology, effective management is challenging. The aetiology and pathophysiology of MDD remain largely unknown given the complex genetic and environmental interactions that are involved. Nonetheless, the aetiology and pathophysiology of MDD have been the subject of extensive research, and there is a vast body of literature that exists. Here we overview the key hypotheses that have been proposed for the neurobiology of MDD and highlight the need for a unified model, as many of these pathways are integrated. Key pathways discussed include neurotransmission, neuroinflammation, clock gene machinery pathways, oxidative stress, role of neurotrophins, stress response pathways, the endocannabinoid and endovanilloid systems, and the endogenous opioid system. We also describe the current management of MDD, and emerging novel therapies, with particular focus on patients with treatment-resistant depression (TRD).
Indexed as
Identifiers
31612411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.